Efficacy and safety of ultra-long-acting insulin degludec

Ammar Wakil, Stephen Atkin

Research output: Contribution to journalReview article

9 Citations (Scopus)


All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalTherapeutic Advances in Endocrinology and Metabolism
Issue number2
Publication statusPublished - 2012
Externally publishedYes



  • hypoglycaemia
  • insulin degludec
  • type 1 and type 2 diabetes
  • ultra-long-acting basal insulin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this